No abstract

No abstract

No abstract

Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (COVID-19) mortality. This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematologic malignancies and to determine risk factors associated with all-cause mortality. Methods: A multi-center, observational retrospective analysis of patients with hematologic malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study. Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematologic malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p<0.001) and had more comorbidities (p<0.05). There were significantly more patients with low lymphocyte percentage (p<0.001), thrombocytopenia (p<0.001), and high CRP (p<0.001) in the non-survived patients. Cardiac comorbidities, (p=0.016), cytotoxic chemotherapy (p=0.024), low lymphocyte percentage (p=0.025), thrombocytopenia (p<0.0001), and high CRP values (p=0.017) were the independent risk factors for the prediction of mortality. Conclusions: In patients with hematologic malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Cardiac diseases, cytotoxic chemotherapy, lymphopenia, thrombocytopenia, and high CRP are the independent risk factors for mortality in hematologic malignancy patients with COVID-19. Keywords: Covid; Hematologic Malignancy; Cytotoxic chemotherapy.

Background:A higher amylase than normal concentration may reflect one of several medical conditions, including acute inflammation of the pancreas, perforated peptic ulcer, torsion of an ovarian cyst, strangulation ileus, mesenteric ischemia, macroamylasemia, renal failure and mumps. In addition; amylase production by epithelial carcinomas has been well documented. But hyperamylasemia associated with multiple myeloma has been reported only in a few cases. We report a case with hyperamylasemia associated with multiple myeloma in this paper because of rarity.Case report:We report a 64 year old male patient with multiple myeloma. He had hyperamylasemia and no evidence of pancreatic and salivary gland disease, renal failure. The patient had relapse disease after autologous bone marrow transplant. Amylase value is high correlated with his disease status. Combined chemotherapy (lenalidomide 25 mg once daily orally on days 1–21 and dexamethosone 40 mg/day, days 1–4 of repeated 28-day cycles) was started to our patient for multiple myeloma. The amylase level decresed to a normal level after 28 days.Conclusion:Paraneoplastic hyperamylasaemia as a marker to monitor disease progression and treatment response in cases with multiple myeloma. It related to extensive extra-medullary spread, extensive bone destruction and shorter survival time.